The present study was conducted to analyze Organophosphorus poisoning patients with respect to serum cholinesterase level and get an idea of its correlation with various other factors to predict clinical course, severity and outcome of treatment. This was a retrospective study of 6 months duration (July 1st – December 31st 2017) conducted in General Medicine and Record & Statistics Department of tertiary care hospital. The study was approved by the Institutional Ethics Committee. All the patients of OP poisoning and patients with clinical features suggestive of OP poisoning, irrespective of age/sex were included in the study. Non-OP poisoning patients, patients with renal failure and with multiple poisoning with other drugs such as opioids, diazepam, barbiturate, etc were excluded. Out of 262 poisoning cases in this study, 46 cases were OP poisoning. Sex ratio (M:F) is 3.6:1 and 16-30 yrs age group was most commonly affected, unmarried and belonging to rural area. Suicidal being the most common manner of OP poisoning and by oral route. Family stress in case of suicidal poisoning and alcohol influence for accidental poisoning emerged to be the most common reasons. The mean SCE level is 4491 ± 4128 U/L. Most cases were found to be in the range of 1000-2000U/L (32.6%). Mortality rate in this study was only 13%, due to the close proximity of medical facilities available in our region. Vomiting was found to be the most common clinical feature, followed by giddiness and miosis. Hospital stay duration was seen to be more in patients with low level of SCE (< 2000 U/L). Duration of ventilation needed was more among the patients with low level of SCE (< 2000 U/L). But, SCE level did not show any correlation with treatments outcome, blood pressure, respiratory rate, breathlessness, vomiting and unconsciousness. Treatments outcome worsened with increase in gap between OP consumption and hospital admission.
<p><strong>Background:</strong> Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures. Depressive disorders are the most common psychiatric co-morbidity in patients with epilepsy. Early detection and treatment improve overall health related quality in these patients.<strong></strong></p><p><strong>Methods: </strong>A prospective cross sectional observational study was conducted across 6 months (December 2018-May 2019) in a tertiary care hospital. The present study included 50 registered patients and various socio-demographic factors like age, sex, marital status, literacy, drug compliance and status of seizure control etc. were evaluated in regards to prevalence and severity of depression.</p><p><strong>Results: </strong>Out of 50 patients, 27 patients (54%) showed signs of depression. Out of which 10 patients (20%) showed signs of mild depression, 6 patients (12%) showed signs of moderate depression, 7 patients (14%) showed signs of moderately severe depression whereas 4 patients (8%) showed signs of severe depression and there was a strong association of drug compliance, current epilepsy status and last seizure episode with various degree of depression.</p><p><strong>Conclusions: </strong>Depression is an illness with a significant morbidity and mortality. Its association with epilepsy is very strong. Various factors contribute to depression which include compliance of drugs, last seizure episode, current status of epilepsy, etc. Unfortunately, depression among epileptics is very much under diagnosed and therefore untreated. A through psychiatric assessment should be done in these patients with epilepsy for depression and appropriate treatment should be instituted.</p>
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.